Natriumbikarbonat Fresenius Kabi (Sodium Hydrogen Carbonate)

Sodium Hydrogen Carbonate, the active ingredient in Natriumbikarbonat Fresenius Kabi, is an excipient presented as a sterile solution for injection for intravenous use. It provides bicarbonate ions to raise plasma pH and correct metabolic acidosis, and is also employed to alkalinize urine in clinical settings.

GNH USA supplies Natriumbikarbonat Fresenius Kabi as a licensed, GDP‑compliant product sourced from the European Union, delivering reliable batches to hospitals, transplant centres, oncology units and pharmacy chains worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support international distribution.

Natriumbikarbonat is an intravenous electrolyte replenisher that addresses acid‑base disturbances.

Metabolic acidosis: rapidly raises plasma bicarbonate concentration to normalize pH in patients with acute or chronic acid accumulation. Correction of acid‑base disturbances: provides buffering capacity during surgery, trauma or renal failure to maintain systemic homeostasis. Alkalinization of urine: elevates urinary pH to enhance excretion of acidic drugs or prevent calcium‑oxalate stone formation.

Intravenous administration of sodium hydrogen carbonate may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects: - Injection site pain: mild discomfort or erythema at the infusion site. - Hypernatremia: elevated serum sodium levels causing thirst or mild edema. - Metabolic alkalosis: excessive rise in blood pH leading to tingling or nausea. - Hypocalcemia: reduced calcium levels manifesting as muscle cramps.

Serious or Rare Side Effects: - Volume overload: pulmonary edema in patients with compromised cardiac function. - Severe hyperkalemia: paradoxical increase in potassium in certain renal conditions. - Allergic reaction: anaphylaxis with rash, bronchospasm, or hypotension. - Intracellular shift of potassium: can precipitate arrhythmias.

Before using Natriumbikarbonat, clinicians should consider several safety and handling precautions. - Indication assessment: confirm metabolic acidosis or need for urine alkalinization before administration. - Electrolyte monitoring: regularly check serum sodium, potassium, and bicarbonate levels during therapy. - Cardiac status: avoid rapid infusion in patients with heart failure or fluid overload risk. - Renal function: adjust dose in severe renal impairment to prevent alkalosis. - Concomitant alkalinizing agents: limit use with other bicarbonate‑containing solutions to avoid over‑correction. - Store at ambient temperature: keep in original container, protect from light and moisture, and do not freeze.

Sodium hydrogen carbonate can interact with other medicines, influencing electrolyte balance or drug efficacy.

Major Interactions (Avoid): - Calcium channel blockers: may potentiate hypotension when combined with rapid bicarbonate infusion. - Certain antibiotics (e.g., penicillins): high urinary pH can reduce drug stability and effectiveness. - Loop diuretics: increased risk of metabolic alkalosis and electrolyte disturbances.

Moderate Interactions (Monitor Closely): - ACE inhibitors or ARBs: monitor potassium and renal function due to additive effects on electrolytes. - Antacids containing aluminum or magnesium: may cause precipitation or reduced absorption of other oral drugs. - Insulin therapy: rapid correction of acidosis can alter glucose utilization, requiring insulin dose adjustment.